Agetech innovation round-up; featuring academia, business and research concerns.

LONGEVITY science is entering the mainstream with the launch of the world’s first healthspan PhD and the creation of the world’s first ‘longevity board’ for AI-enabled research.

Switzerland’s Geneva College of Longevity Science (GCLS) and its Romanian partner Ovidius University of Constanța say their four-year PhD doctoral programme represents a milestone in the evolution of longevity science.

Dominik Thor, President of GCLS, said: “Longevity medicine has reached a point where the science is advancing faster than the institutions required to translate it responsibly into healthcare.

“With this PhD, we are building the academic and research infrastructure needed to support the field’s long-term development.”

The academic partners say that ‘advances in ageing biology, genomics, and digital health have created new opportunities to move beyond reactive care toward proactive risk management and healthspan preservation’.

The PhD in Longevity Sciences addresses this gap by providing structured doctoral training in:

-Biology of ageing and longevity pathways

-Biomarkers and measurement of biological age

-Preventive, risk-stratified, and healthspan-oriented medicine

-Epidemiology of ageing populations

-Ethical, regulatory, and health system considerations

The program reflects a broader shift in medicine; from treating disease after onset to addressing the underlying drivers of disease.

Meanwhile, AI-driven Insilico Medicine, a clinical-stage US biotechnology company, has launched the industry’s first ‘longevity board’.

It aims to deliver scientific oversight and strategic guidance for AI-enabled ageing research and drug discovery, advancing the shift from reactive to proactive care.

The initial board is composed of high-profile scientists involved in ageing and disease research, including chairman Dr Andrew Adams, of Eli Lilly, and Chemistry Nobel Laureate Dr Michael Levitt, of Insilico.

Dr Levitt, said: “Ageing is not a single problem – it is a deeply interconnected web of molecular and cellular processes, and only by targeting that complexity systematically, with AI tools sophisticated enough to map it, do we have a realistic chance of extending not just lifespan but healthspan.

“I am proud to be part of an effort that is serious, scientifically grounded, and ambitious enough to matter.”

These latest developments should help deliver in one area of pressing need in the longevity space; ie the move from pre-clinical claims to evidenced, human, clinical trials

The disconnect between bold market claims and the level of human evidence needed for substantiation is one of the biggest gaps in the ageing/vitality space, says Dr Anu Turpeinen, nutrition research manager at European dairy giant Valio.

She said: “Many ingredients promoted for cellular rejuvenation or lifespan extension are still primarily supported by preclinical research, such as cell or animal studies.

“While these models can provide valuable mechanistic insights, human biology is far more complex, and effects on lifespan in animals do not automatically translate into meaningful outcomes in people.

“In addition, many products rely on surrogate or intermediate markers of aging rather than demonstrating direct reductions in age-related diseases or improvements in functional health.

“Although surrogate markers allow results to be observed within realistic timeframes, there is still limited consensus on what constitutes a robust and validated biomarker of aging.”